Childhood Cancer

You are here

Home » Grants » All grants tagged with "Juvenile Myelomonocytic Leukemia (JMML)"

All grants tagged with "Juvenile Myelomonocytic Leukemia (JMML)"

Targeting Novel Inflammatory Signaling Pathways in Juvenile Myelomonocytic Leukemia
Santhosh Kumar Pasupuleti, PhD
Indiana University
'A' Award Grants, Awarded 2024
Therapeutic targeting of clonal hematopoiesis in RUNX1 mutant FPDMM
Robert Bowman, Ph.D.
University of Pennsylvania
RARE Grant Program (Research Accelerating RUNX1 Exploration), Awarded 2024
CLL-1 CAR-T cells with or without trametinib for the treatment of JMML
Elliot Stieglitz, MD
The Regents of the University of California San Francisco
R Accelerated Award Grants, Awarded 2023
Targeting Oncogenic RAS in Pediatric Leukemia
Loren Walensky, MD/PhD
Dana-Farber Cancer Institute
Innovation Grants, Awarded 2018
Role of Polycomb Repressive Complex 2 (PRC2) Mutations in Juvenile Myelomonocytic Leukemia
Emily Young
Boston Children’s Hospital
POST Program Grants, Awarded 2017
Transcriptional Effectors of Activated RAS Signaling in Juvenile Myelomonocytic Leukemia
Alan Cantor, MD, PhD
Boston Children’s Hospital
Innovation Grants, Awarded 2015
Targeting Secondary Mutations in Juvenile Myelomonocytic Leukemia
Elliot Stieglitz, MD
University of California San Francisco
Young Investigator Grants, Awarded 2015
Modeling Juvenile Myelomonocytic Leukemia with Patient-Derived Induced Pluripotent Stem Cells
Mitchell Weiss, M.D., Ph.D.
Children’s Hospital of Philadelphia
Innovation Grants, Awarded 2014
Natural Killer Cell-mediated Lysis of Juvenile Myelomonocytic Leukemia Cells
Shannalee Martinez
University of Texas
POST Program Grants, Awarded 2012
Investigating therapeutic strategies for JMML: a screen of kinase inhibitors to reveal potential therapeutic strategies and inform future efforts to address aberrant signal transduction.
Wan Xing Hong
University of California San Francisco
POST Program Grants, Awarded 2012

All childhood cancer types

Featured Hero

Seth Walsh

Seth is spunky and can be friends with anyone. After being diagnosed with ALL, Seth endured countless trips out-of-state, four relapses, two CAR T-cell therapies, two bone marrow transplants, and one clinical trial. Today, Seth has reached remission!
Read more »